amyotrophic lateral sclerosis

Search with Google Search with Bing
Information
Disease name
amyotrophic lateral sclerosis
Disease ID
DOID:332
Description
"A motor neuron disease that is characterized by muscle spasticity, rapidly progressive weakness due to muscle atrophy, difficulty in speaking, swallowing, and breathing." [url:http\://en.wikipedia.org/wiki/Amyotrophic_lateral_sclerosis, url:http\://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_ALS.htm]
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
SOD1 21 31,659,693 31,668,931 116
FUS 16 31,180,139 31,191,605 14
MASP2 1 11,026,523 11,047,239 8
TARDBP 1 11,012,654 11,025,492 8
TBK1 12 64,452,120 64,502,114 2
SETX 9 132,261,356 132,354,986 2
HNRNPA1 12 54,280,726 54,287,087 2
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT06392126 Active, not recruiting Phase 1/Phase 2 Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS April 16, 2024 April 2025
NCT03984708 Active, not recruiting N/A New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways. January 27, 2020 January 2024
NCT04948645 Active, not recruiting Phase 1 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis September 22, 2021 December 2025
NCT05508074 Active, not recruiting Phase 2 Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) December 2, 2022 January 2025
NCT05035823 Active, not recruiting N/A COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis April 27, 2022 August 2024
NCT05021536 Active, not recruiting Phase 3 Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment October 28, 2021 March 1, 2024
NCT05407324 Active, not recruiting Phase 2 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis November 15, 2022 May 2027
NCT06307301 Active, not recruiting Phase 1 Study in ALS With Abatacept & IL-2 October 28, 2021 October 17, 2024
NCT03690791 Active, not recruiting Phase 3 Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease January 9, 2019 January 30, 2024
NCT05006352 Active, not recruiting Phase 1 A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis August 11, 2021 December 2023
NCT04745299 Active, not recruiting Phase 3 Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS March 23, 2021 May 3, 2026
NCT03268603 Active, not recruiting Phase 2 Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) October 10, 2017 February 2025
NCT03651349 Active, not recruiting Phase 1 To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers February 1, 2021 June 30, 2025
NCT05299658 Active, not recruiting Phase 2 An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS November 13, 2021 December 2024
NCT04494256 Active, not recruiting Phase 1/Phase 2 A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation September 28, 2020 July 15, 2026
NCT01508962 Active, not recruiting PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis November 2013 December 2027
NCT02567136 Active, not recruiting Imaging Biomarkers in ALS September 2015 September 2025
NCT05218668 Active, not recruiting Phase 2 Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) December 22, 2021 July 2024
NCT05981040 Active, not recruiting Phase 2 Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis October 27, 2023 September 30, 2024
NCT06209515 Active, not recruiting Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study January 1, 2022 December 31, 2027
NCT04997954 Active, not recruiting Phase 4 EMERALD TRIAL Open Label Extension Study May 17, 2021 January 2024
NCT05357950 Active, not recruiting Phase 2 A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS May 31, 2022 November 2024
NCT03766321 Active, not recruiting N/A Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients July 1, 2020 February 2025
NCT04993755 Active, not recruiting Phase 2 A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD October 1, 2021 September 1, 2023
NCT05163886 Active, not recruiting Phase 2 Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis December 23, 2021 May 10, 2024
NCT04259255 Active, not recruiting Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) October 21, 2019 March 2024
NCT00801333 Active, not recruiting Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells November 2008 December 2030
NCT03811301 Active, not recruiting N/A [BrainConnexion] - Neurodevice Phase I Trial November 21, 2017 August 27, 2023
NCT05889572 Active, not recruiting Phase 1 Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis June 8, 2023 December 2024
NCT05178810 Active, not recruiting Phase 3 Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis October 18, 2021 June 20, 2024
NCT05349721 Active, not recruiting Phase 2 Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS May 15, 2022 February 28, 2025
NCT03293069 Active, not recruiting Phase 2/Phase 3 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis January 1, 2019 November 2023
NCT03912987 Active, not recruiting TRIAL READY (Clinical Trial Readiness) January 22, 2019 June 2025
NCT04297683 Active, not recruiting Phase 2/Phase 3 HEALEY ALS Platform Trial - Master Protocol July 14, 2020 April 2026
NCT05286372 Approved for marketing An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
NCT05281484 Available Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02
NCT06069934 Available Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)
NCT06408727 Available Intermediate Expanded Access Protocol CNMAu8.EAP04
NCT04081714 Available Intermediate Expanded Access Protocol for ALS
NCT06169176 Available RAPA-501 Therapy for ALS EAP
NCT00600873 Completed Phase 1/Phase 2 R(+)PPX High Dose Treatment of ALS August 2007 January 2009
NCT00613899 Completed Phase 4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) October 2007 October 2008
NCT00620698 Completed Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials May 2007 March 2012
NCT00635960 Completed Phase 2 Growth Hormone in Amyotrophic Lateral Sclerosis March 2007 May 2010
NCT00647296 Completed Phase 2 Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) April 9, 2008 September 4, 2009
NCT00677768 Completed Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) April 2008 November 2015
NCT00706147 Completed Phase 2/Phase 3 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis January 2009 November 2016
NCT00714636 Completed Cerebrospinal Fluid Repository October 2006 October 2008
NCT00714805 Completed Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS) January 2007 November 2016
NCT00716131 Completed Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program April 2007 November 2016
NCT00718393 Completed Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS) June 2007 October 2015
NCT05404867 Completed N/A Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II) June 8, 2022 January 8, 2024
NCT00718458 Completed EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) August 2007 December 2016
NCT00718497 Completed Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population August 2007 May 2012
NCT00748501 Completed Phase 2 Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) September 2008 June 2010
NCT00790582 Completed Phase 2 A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS) May 2008 March 2010
NCT00800501 Completed Phase 1/Phase 2 A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis December 2008 June 2011
NCT00809224 Completed Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS) May 2008 May 2012
NCT00812851 Completed N/A Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) April 2005 April 2008
NCT00833820 Completed Phase 2/Phase 3 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis May 2007 December 2008
NCT00838617 Completed Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS) February 2009 August 2009
NCT00847847 Completed N/A Neuromuscular Transmission in Amyotrophic Lateral Sclerosis March 2009 April 2012
NCT00855400 Completed Phase 1/Phase 2 Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis February 2007 February 2010
NCT00860951 Completed Phase 1/Phase 2 P300 Brain Computer Interface Keyboard to Operate Assistive Technology September 2008 May 2012
NCT00868166 Completed Phase 3 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS April 30, 2009 September 30, 2011
NCT00875446 Completed Phase 1 First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis May 13, 2009 September 9, 2011
NCT00877604 Completed Phase 2 Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis June 2008 April 2012
NCT00879593 Completed N/A Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS) April 2009 January 2017
NCT00919555 Completed Phase 1/Phase 2 Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) June 2008 March 2012
NCT00925847 Completed Phase 2 Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis June 2009 April 2011
NCT00931944 Completed Phase 2 Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211) July 2009 July 2013
NCT00956488 Completed Phase 1/Phase 2 Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis September 2008 September 2010
NCT00956501 Completed Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS) February 2009 February 2011
NCT00958048 Completed N/A Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis January 2009 April 2013
NCT00965497 Completed Phase 3 Escitalopram (Lexapro) for Depression MS or ALS July 2009 March 2010
NCT05202743 Completed Online Self-Compassion Course for pALS (Compassion pALS) December 17, 2021 June 1, 2022
NCT00983983 Completed Phase 2 High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis October 2009 May 2013
NCT01020331 Completed Phase 2 Memantine Therapy in Amyotrophic Lateral Sclerosis June 2005 October 2009
NCT01051882 Completed Phase 1/Phase 2 Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. June 2011 March 2013
NCT05176093 Completed Phase 2 A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis November 14, 2021 December 29, 2022
NCT01089010 Completed Phase 2 A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) March 2010 November 2010
NCT01090674 Completed Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases June 2007 July 2013
NCT01091142 Completed Phase 1 Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) July 2010
NCT01119001 Completed N/A A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis February 2010 August 2010
NCT01123148 Completed N/A A P300 Brain Computer Interface to Operate Power Wheelchair Tilt January 2010 August 2010
NCT01123200 Completed N/A An In-home Study of Brain Computer Interfaces January 2010 May 2011
NCT01142856 Completed Phase 1 Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS) June 2010 April 2011
NCT01154283 Completed N/A Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients January 2008 October 2011
NCT01160263 Completed Phase 3 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls October 2012 October 2014
NCT01160367 Completed N/A Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life August 26, 2010 March 26, 2014
NCT01254539 Completed Phase 1/Phase 2 Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA) October 2010 November 20, 2015
NCT01257581 Completed Phase 2 Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) March 2011 February 2013
NCT01259050 Completed Phase 1/Phase 2 Safety Study of High Doses of Zinc in ALS Patients October 2010 March 2012
NCT01281189 Completed Phase 3 Phase 3 Study of Dexpramipexole in ALS March 2011 November 2012
NCT01281631 Completed Phase 2 A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) February 2011 September 2012
NCT01285583 Completed Phase 2/Phase 3 Safety Extension Study of TRO19622 in ALS October 2010 March 2012
NCT01363401 Completed Phase 1/Phase 2 Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis February 2011 August 2013
NCT05136885 Completed Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose February 21, 2022 August 25, 2023
NCT01378676 Completed Phase 2 A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) June 2011 March 2012
NCT01424163 Completed Phase 1 Dexpramipexole Japanese PK Study August 2011 February 2012
NCT01424176 Completed Phase 1 Dexpramipexole Renal PK Study July 2011 January 2012
NCT01449578 Completed Phase 1 Dexpramipexole SAD/MAD Study November 2011 January 2012
NCT01486849 Completed Phase 2 Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) November 2011 March 2012
NCT01495390 Completed A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers November 2011 December 31, 2016
NCT01504009 Completed N/A Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS) May 2011 June 2016
NCT01511029 Completed Phase 1 Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate) January 2012 May 2012
NCT01521728 Completed N/A Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) January 2012 February 2016
NCT05039268 Completed Phase 2 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) November 25, 2021 September 12, 2022
NCT01536249 Completed Phase 1 Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) March 2012 April 2012
NCT01551940 Completed Phase 2 Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea February 2012 March 2014
NCT05019014 Completed Olfactory Deficits in Neurologic Disease August 10, 2011 July 3, 2020
NCT01592084 Completed Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis April 2008 September 2011
NCT01609283 Completed Phase 1 A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis May 2012 January 31, 2019
NCT01639391 Completed N/A Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study November 29, 2012 March 17, 2015
NCT01640067 Completed Phase 1 Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS) December 2011 December 2015
NCT01641965 Completed N/A Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients April 2012 December 2015
NCT05003167 Completed N/A Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS January 1, 2021 June 1, 2022
NCT01709149 Completed Phase 2 Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) October 2012 March 2014
NCT01753076 Completed Phase 2 Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis December 20, 2012 January 22, 2015
NCT01758510 Completed Phase 1 Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis December 2012 April 10, 2017
NCT01759797 Completed Phase 1 Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS January 2013 March 2014
NCT01771640 Completed Phase 1 Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS August 2013 December 2014
NCT01777646 Completed Phase 2 Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) December 2012 September 2015
NCT01786174 Completed Phase 2 Gilenya in Amyotrophic Lateral Sclerosis (ALS) August 2013 May 2015
NCT01823380 Completed N/A Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype September 2012 September 2015
NCT01825551 Completed Phase 2/Phase 3 The Effect of GCSF in the Treatment of ALS Patients November 2012 November 2013
NCT01854294 Completed Phase 2 GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) August 2013 July 2014
NCT01874808 Completed From Movement Preparation to Gait Execution in ALS June 21, 2013 December 21, 2015
NCT01879241 Completed Phase 2 Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis June 2013 August 2016
NCT01889043 Completed Monitoring of Non-invasive Ventilation During Sleep in ALS January 2012
NCT04953286 Completed N/A Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis September 17, 2021 September 30, 2023
NCT01906658 Completed Phase 2 A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis July 2013 December 2014
NCT01911130 Completed Longitudinal Study of Outcomes Measures in ALS Trials July 2013 March 2016
NCT01925196 Completed Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation September 30, 2013
NCT01933321 Completed Phase 2/Phase 3 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) September 2012 June 2014
NCT04952025 Completed Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis January 1, 2015 January 31, 2021
NCT01948102 Completed Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples August 20, 2008 April 4, 2017
NCT04950231 Completed Investigation on Home Care Needs of ALS Patients and Their Caregivers September 1, 2020 May 1, 2021
NCT01955369 Completed Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate October 2009 September 2015
NCT04948346 Completed Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis January 31, 2018 June 1, 2021
NCT04947436 Completed N/A ALS and Airway Clearance (ALSAC) Therapy January 25, 2012 September 17, 2017
NCT04939818 Completed Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders June 14, 2021 September 15, 2022
NCT01995903 Completed N/A Developing a Discrimination Model to Diagnose ALS April 2012 October 2015
NCT04889248 Completed N/A Inspiratory Muscle Training With Powerbreath Device in Patients With ALS May 17, 2021 November 12, 2021
NCT04875949 Completed N/A Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB) April 2016 April 2019
NCT02011204 Completed Study of Electrical Impedance Myography (EIM) in ALS November 2013 March 2016
NCT02039401 Completed Phase 1/Phase 2 Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis March 2014 December 2017
NCT04840823 Completed Phase 1/Phase 2 Enoxacin for Amyotrophic Lateral Sclerosis (ALS) March 26, 2021 November 15, 2023
NCT02059759 Completed Phase 2 Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 September 2015 May 2016
NCT02104921 Completed Innovative Ultrasound Technology in Neuromuscular Disease December 1, 2013 March 1, 2020
NCT04821479 Completed Phase 1/Phase 2 Repeated Mesenchymal Stem Cell Injections in ALS January 1, 2016 December 31, 2020
NCT02118727 Completed Phase 2 Therapy in Amyotrophic Lateral Sclerosis (TAME) November 7, 2018 July 22, 2021
NCT02166944 Completed Phase 1/Phase 2 Tamoxifen Treatment in Patients With Motor Neuron Disease April 2014 September 18, 2019
NCT04819555 Completed Frequency of SOD1 and C9orf72 Gene Mutations in French ALS April 30, 2021 May 15, 2023
NCT02236065 Completed N/A Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders August 2014 July 2016
NCT02238626 Completed Phase 2 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) September 2014 December 2017
NCT04800926 Completed N/A Xavier Electromyographic Wheelchair Control for Limited Mobility Patients January 11, 2019 October 30, 2019
NCT04797845 Completed N/A Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home. April 12, 2021 September 18, 2023
NCT02288091 Completed Phase 1 A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) January 2015 March 2016
NCT02290886 Completed Phase 1/Phase 2 A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral July 2014 March 2, 2022
NCT02306109 Completed N/A Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS) January 2015 April 2018
NCT02306590 Completed N/A Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis February 2015 September 2018
NCT02313402 Completed N/A A New Eye-based Communication Device for ALS Patients June 2014 April 2015
NCT04788745 Completed Phase 2 Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS) June 29, 2021 May 24, 2023
NCT02325375 Completed sCD163 in ALS Patients December 2014 February 2016
NCT04719403 Completed N/A Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers May 12, 2021 June 9, 2022
NCT02383654 Completed Phase 1 Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis January 2015 January 2016
NCT02405182 Completed MRI Biomarkers in ALS September 2014 April 1, 2019
NCT02418546 Completed N/A Electronic-health Application To Measure Outcomes REmotely Clinical Trial April 2015 March 2018
NCT02437110 Completed Phase 1 HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) April 1, 2019 May 9, 2023
NCT02447952 Completed N/A Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis June 30, 2015 June 1, 2017
NCT02450552 Completed Phase 2 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects June 2015 February 2018
NCT02460679 Completed Phase 2 Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) January 14, 2016 February 23, 2018
NCT02469896 Completed Phase 2 A Trial of Tocilizumab in ALS Subjects November 2015 July 11, 2018
NCT00004771 Completed Phase 2 Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease October 1992
NCT02479802 Completed Phase 2 Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis November 2014 June 2016
NCT02487407 Completed Phase 2 Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis July 2015 June 2017
NCT02492516 Completed Phase 1 Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS September 2014 April 2017
NCT02496767 Completed Phase 3 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year September 3, 2015 September 27, 2017
NCT02507713 Completed Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS) September 2013
NCT04654689 Completed Phase 2 Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients November 20, 2021 February 4, 2023
NCT02548663 Completed N/A Sport Therapy and Osteopathy Manipulative Treatment in ALS June 2014 May 2015
NCT02572479 Completed Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS) October 2015 October 2018
NCT02574390 Completed Answer ALS: Individualized Initiative for ALS Discovery December 2015 January 1, 2020
NCT02582385 Completed In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS) October 2012 February 2015
NCT04632225 Completed Phase 2 Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis February 9, 2021 August 31, 2022
NCT02590276 Completed N/A Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) October 8, 2015 October 27, 2020
NCT02611674 Completed Methodology Study of Novel Outcome Measures to Assess Progression of ALS January 6, 2016 August 1, 2019
NCT02623699 Completed Phase 3 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) January 20, 2016 July 16, 2021
NCT02645461 Completed N/A Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS January 2014 December 2015
NCT02655614 Completed Phase 1 A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis May 31, 2016 March 16, 2020
NCT04615923 Completed Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen D Pridopidine December 18, 2020 July 14, 2022
NCT02670226 Completed N/A Muscular Biomarkers in Amyotrophic Lateral Sclerosis March 29, 2016 December 9, 2019
NCT02675075 Completed DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS January 1, 2016 December 31, 2017
NCT02682030 Completed N/A The Use of Airway Clearance Devices in ALS March 2016 December 2018
NCT02710110 Completed Early Phase 1 Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS) April 2016 February 7, 2019
NCT02710162 Completed Early Phase 1 Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS) April 2016 December 19, 2017
NCT02714036 Completed Phase 1/Phase 2 A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) May 6, 2016 June 30, 2020
NCT02750982 Completed N/A Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. July 2016 August 2018
NCT02759003 Completed N/A Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting March 2011 March 2014
NCT02794857 Completed Phase 2 Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation August 29, 2016 December 12, 2017
NCT04559009 Completed COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry October 15, 2020 January 31, 2023
NCT02851914 Completed Early Phase 1 SSRIs vs. TCAs for Depression in ALS Patients July 21, 2015 May 30, 2019
NCT02852278 Completed A Patient Centric Motor Neuron Disease Activities of Daily Living Scale December 2016 September 13, 2019
NCT02868580 Completed Phase 2 Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). October 2016 December 2018
NCT04557410 Completed Phase 1 Open Label Study: Treatment of ALS Fatigue With PolyMVA September 23, 2020 May 25, 2021
NCT02870634 Completed Phase 1 Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND November 16, 2016 January 30, 2020
NCT02872142 Completed Phase 2 Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis August 29, 2016 August 15, 2019
NCT04516096 Completed Phase 2/Phase 3 A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) November 22, 2020 January 31, 2023
NCT02880033 Completed N/A Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes February 2011 March 2020
NCT03705390 Completed Phase 2 A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS) March 29, 2019 July 28, 2021
NCT03683875 Completed Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis October 1, 2018 March 10, 2020
NCT00005766 Completed Phase 2 Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
NCT00007722 Completed Amyotrophic Lateral Sclerosis (ALS) Gulf War Study July 2000 March 2003
NCT00011154 Completed Exogenous Toxicants and Genetic Susceptibility in ALS September 1996 August 2002
NCT00021697 Completed Phase 3 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS January 2001 April 2002
NCT00023075 Completed Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis August 2001 August 2003
NCT00035815 Completed Phase 3 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial June 2003 December 2007
NCT00036413 Completed Phase 2 A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis January 2002 October 2002
NCT00047723 Completed Phase 3 Minocycline to Treat Amyotrophic Lateral Sclerosis January 2003 January 2007
NCT00070993 Completed Phase 2 Creatine for the Treatment of Amyotrophic Lateral Sclerosis December 2002 May 2006
NCT00072709 Completed Phase 2 Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) September 2003 December 2004
NCT00107770 Completed Phase 1/Phase 2 Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) April 2005 September 2007
NCT00116558 Completed N/A Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation August 1, 2004 January 2012
NCT00125203 Completed Phase 2/Phase 3 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) July 2003 August 2007
NCT00136110 Completed Phase 3 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis April 2005 February 2007
NCT00140218 Completed Phase 1/Phase 2 R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis August 2005 December 2006
NCT00140452 Completed Phase 2 Phase II Study Using Thalidomide for the Treatment of ALS February 2005 November 2007
NCT00204464 Completed Phase 2 Study of the Effects Strengthening Exercises in Individuals With ALS December 2004
NCT00230074 Completed Phase 2 A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) November 2004 February 2005
NCT00243932 Completed Phase 2 Clinical Trial of High Dose CoQ10 in ALS April 2005 March 2008
NCT00298597 Completed Phase 2 Influence of G-CSF and EPO on Associative Learning and Motor Skills March 2006 March 2009
NCT00302198 Completed Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org January 2006 February 2010
NCT00324454 Completed Phase 2 Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease May 2006 June 2008
NCT00326625 Completed Phase 2 Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) July 27, 2006 June 17, 2008
NCT00337402 Completed Effects of Gastrostomy on Amyotrophic Lateral Sclerosis January 2002 June 2005
NCT00339976 Completed Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis August 6, 2002 April 21, 2008
NCT00349622 Completed Phase 3 Clinical Trial Ceftriaxone in Subjects With ALS July 2006 November 2012
NCT00353665 Completed Phase 2/Phase 3 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) July 2005 January 2009
NCT00355576 Completed Phase 2 Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis July 2006 May 2007
NCT00372879 Completed Phase 3 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS December 2006 August 2010
NCT00377351 Completed Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort September 11, 2006 August 3, 2010
NCT00386464 Completed Phase 2/Phase 3 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement April 2002 September 2007
NCT00397423 Completed Phase 2 G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response December 2006 August 2007
NCT00409721 Completed Phase 2 The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS) March 2007 December 2010
NCT00537641 Completed Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) May 2007 June 2011
NCT00542412 Completed Phase 4 CARE Canadian ALS Riluzole Evaluation January 2001 December 2004
NCT05945784 Completed Exploring Accessible Beauty for Individuals With Upper Extremity Deficits July 21, 2023 September 29, 2023
NCT00580593 Completed Phase 1 Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS) April 2007 March 2012
NCT05742828 Completed N/A Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS) September 20, 2017 March 31, 2020
NCT03516994 Completed N/A Reducing Disparities in the Quality of Advance Care Planning for Older Adults August 1, 2018 April 15, 2024
NCT03883581 Completed Phase 1/Phase 2 Impact of Nuedexta on Bulbar Physiology and Function in ALS July 25, 2019 November 22, 2021
NCT03520517 Completed Phase 1 Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS February 2, 2018 October 8, 2018
NCT03876002 Completed Phase 1 Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET June 28, 2016 February 7, 2018
NCT03868345 Completed Speech Analysis in ALS Patients February 18, 2019 April 30, 2021
NCT03560661 Completed Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS) July 5, 2018 December 23, 2019
NCT03851302 Completed N/A Effects of Remote Ischemic Conditioning on Hand Use in Individuals With Spinal Cord Injury and Amyotrophic Lateral Sclerosis October 28, 2019 October 31, 2022
NCT03793868 Completed Early Phase 1 Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis December 4, 2018 September 1, 2020
NCT03792490 Completed Phase 2 Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS February 20, 2019 November 1, 2023
NCT03613038 Completed N/A A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria July 15, 2017 February 28, 2022
NCT03618966 Completed Phase 2 Neuromuscular Magnetic Stimulation in ALS Patients November 1, 2014 November 1, 2017
NCT03626012 Completed Phase 1 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis September 10, 2018 November 17, 2021
NCT03706391 Completed Study of ALS Reversals 4: LifeTime Exposures September 26, 2018 June 1, 2020
NCT03693781 Completed Phase 2 Colchicine for Amyotrophic Lateral Sclerosis April 10, 2019 January 3, 2023
NCT04499963 Completed Phase 2 Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) August 28, 2020 August 30, 2022
NCT02893605 Completed Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis March 2014 May 2017
NCT02916966 Completed Environmental Exposure and Neurological Diseases Questionnaire October 2016 September 2023
NCT02942953 Completed Diaphragmatic Pacer Placement: Anesthetic Management (DP) June 2015 October 2015
NCT02943850 Completed Phase 1 CNS10-NPC-GDNF for the Treatment of ALS April 1, 2017 October 18, 2019
NCT02962050 Completed Delineating Swallowing Impairment and Decline in ALS May 31, 2017 February 16, 2023
NCT00005674 Completed Phase 2 Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]
NCT03016897 Completed ALS Testing Through Home-based Outcome Measures February 22, 2017 September 30, 2019
NCT04455542 Completed Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis August 1, 2017 May 1, 2019
NCT04454840 Completed Early Phase 1 Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis May 1, 2016 May 1, 2019
NCT03039673 Completed Phase 2 MIROCALS: Modifying Immune Response and OutComes in ALS June 19, 2017 July 22, 2021
NCT04440644 Completed Italian Validation of the Beaumont Behavioural Inventory (BBI) September 17, 2019 November 30, 2020
NCT04436510 Completed Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen B Verdiperstat July 28, 2020 December 6, 2022
NCT04436497 Completed Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen A Zilucoplan July 29, 2020 May 4, 2022
NCT03073239 Completed Amyotrophic Lateral Sclerosis: a New Paradigm December 2016 June 2018
NCT04414345 Completed Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen C CNM-Au8 July 30, 2020 March 7, 2023
NCT03085706 Completed N/A Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis October 2010 June 2013
NCT04322149 Completed Phase 2 Multiple Doses of AT-1501-A201 in Adults With ALS October 16, 2020 March 24, 2022
NCT03095729 Completed Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY) April 26, 2017 July 4, 2019
NCT03095989 Completed N/A An Online Mindfulness Intervention for People With ALS and Their Caregivers January 2015 February 2019
NCT04313166 Completed Phase 2 Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 March 19, 2020 February 15, 2022
NCT03113630 Completed N/A Virtual Task in Amyotrophic Lateral Sclerosis February 2, 2016 October 4, 2016
NCT03114215 Completed Phase 2 Effect of MD1003 in Amyotrophic Lateral Sclerosis June 29, 2016 December 2017
NCT03127514 Completed Phase 2 AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) June 22, 2017 November 24, 2019
NCT04305639 Completed The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)" September 1, 2020 April 8, 2021
NCT03150290 Completed N/A Brown Adipose Tissue in ALS October 26, 2017 April 1, 2019
NCT03160898 Completed Phase 2 A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) July 24, 2017 March 7, 2019
NCT03168711 Completed Phase 2 Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) October 1, 2017 January 7, 2020
NCT03186040 Completed Phase 1/Phase 2 Open-label Clinical Trial of Lacosamide in ALS July 13, 2017 May 31, 2020
NCT03192358 Completed Physiological Flow of Liquids Used in Dysphagia Management (Neuro) November 1, 2017 December 31, 2020
NCT03201991 Completed N/A ALS Study Determining Various Biomarkers and Strength Comparison After Exercise May 1, 2017 April 18, 2018
NCT03202017 Completed N/A Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS March 1, 2018 December 30, 2022
NCT03204500 Completed Phase 2 Dual Treatment With Lithium and Valproate in ALS. May 2016 August 2019
NCT04257760 Completed N/A Evaluation of Palliative Care for Patients With ALS and Their Caregivers October 8, 2020 October 30, 2022
NCT03237741 Completed Phase 1 Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants August 7, 2017 December 14, 2017
NCT04245709 Completed Phase 2 Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis February 10, 2020 March 10, 2021
NCT04172792 Completed Phase 1 Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS) November 26, 2019 April 5, 2021
NCT03293394 Completed N/A Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis October 2, 2017 July 1, 2018
NCT04165850 Completed Phase 2 Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS November 25, 2019 January 19, 2021
NCT04104373 Completed The Ontario Neurodegenerative Disease Research Initiative July 7, 2014 April 30, 2018
NCT03324399 Completed N/A A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS June 1, 2017 June 26, 2019
NCT03326622 Completed N/A Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients July 1, 2013 June 30, 2015
NCT04098406 Completed Phase 2 Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) December 19, 2019 July 13, 2021
NCT03359538 Completed Phase 2 Rapamycin Treatment for ALS September 19, 2017 February 15, 2022
NCT04051333 Completed The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2) March 30, 2020 December 31, 2021
NCT04026581 Completed Real World Testing of a Brain-Computer Interface June 5, 2019 September 30, 2023
NCT03986671 Completed N/A Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx April 30, 2019 March 26, 2021
NCT03378375 Completed Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation November 1996 November 2014
NCT03382392 Completed Hypermetabolism in ALS Using Six REE Formulas November 1996 November 2014
NCT03411863 Completed N/A Cervical Electrical Stimulation for ALS January 4, 2018 June 1, 2021
NCT03427086 Completed Phase 2 Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis January 29, 2018 May 10, 2021
NCT03975608 Completed N/A Psychological Therapy for Patients With ALS February 11, 2019 November 15, 2020
NCT03456882 Completed Phase 2 The Effect of RNS60 on ALS Biomarkers May 30, 2017 May 30, 2021
NCT03464903 Completed Study of ALS Reversals 2: Genetic Analyses June 22, 2018 December 1, 2023
NCT03945279 Completed Phase 1 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis May 30, 2019 June 21, 2021
NCT03481348 Completed Phase 1/Phase 2 Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis February 1, 2018 July 21, 2020
NCT03487263 Completed Phase 1 Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease October 1, 2017 December 30, 2018
NCT03488524 Completed Phase 2 Open Label Extension Study of AMX0035 in Patients With ALS March 29, 2018 November 1, 2021
NCT03489200 Completed N/A EH301 for the Treatment of ALS January 2017 June 2017
NCT03929068 Completed Phase 1 Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis May 13, 2019 July 8, 2022
NCT03491462 Completed Phase 3 Arimoclomol in Amyotropic Lateral Sclerosis July 31, 2018 December 18, 2020
NCT03505021 Completed Phase 3 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS June 21, 2018 July 23, 2020
NCT04961450 Enrolling by invitation Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China June 24, 2021 December 31, 2030
NCT05725759 Enrolling by invitation Rehabilitation in SOD1 ALS Treated With Tofersen November 8, 2022 December 2024
NCT05842941 Enrolling by invitation Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen G DNL343 May 24, 2023 August 2025
NCT02327845 Enrolling by invitation Phenotype, Genotype & Biomarkers in ALS and Related Disorders April 2015 July 2025
NCT05740813 Enrolling by invitation Phase 2/Phase 3 HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 March 23, 2023 October 2024
NCT05106569 Enrolling by invitation Telespirometry in Amyotrophic Lateral Sclerosis (ALS) April 28, 2021 December 30, 2024
NCT05619783 Enrolling by invitation Phase 3 Extension Study Evaluating The Safety And Tolerability of AMX0035 December 29, 2022 August 2026
NCT05119387 Enrolling by invitation Genetic Study of Amyotrophic Lateral Sclerosis in Norway August 1, 2019 December 31, 2030
NCT01459302 Enrolling by invitation Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders January 2009 October 2024
NCT04309604 No longer available IC14 for ALS Patients Expanded Access
NCT05597436 No longer available Intermediate-Sized Expanded Access Study
NCT04681118 No longer available Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
NCT03537807 No longer available Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04514952 No longer available Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
NCT06454682 Not yet recruiting Early Phase 1 An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (ALS) July 2024 August 2031
NCT02478450 Not yet recruiting Phase 1/Phase 2 Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) March 2024 December 2025
NCT02988297 Not yet recruiting Phase 2 Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis October 2024 November 2026
NCT04089696 Not yet recruiting N/A Validation of the "ExSpiron©" in Patients With ALS September 2025 September 2025
NCT04220190 Not yet recruiting Phase 2/Phase 3 RAPA-501 Therapy for ALS September 2024 July 1, 2025
NCT04332198 Not yet recruiting N/A Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA) July 2023 October 2024
NCT05105958 Not yet recruiting Phase 2 Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis December 1, 2025 March 1, 2026
NCT05151211 Not yet recruiting Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis May 30, 2024 March 1, 2025
NCT05297487 Not yet recruiting N/A Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study. July 1, 2025 July 1, 2028
NCT05423678 Not yet recruiting Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients July 2024 July 2026
NCT05470478 Not yet recruiting N/A iBCI Optimization for Veterans With Paralysis September 1, 2024 June 30, 2026
NCT05860244 Not yet recruiting Phase 2 Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients September 2024 July 2025
NCT05880563 Not yet recruiting Phase 1 Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) August 2023 September 2026
NCT05892822 Not yet recruiting Amyotrophic Lateral Sclerosis Registry June 15, 2023 December 31, 2024
NCT06100276 Not yet recruiting Phase 1/Phase 2 Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) May 30, 2024 March 30, 2031
NCT06119087 Not yet recruiting N/A Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study June 1, 2024 December 31, 2025
NCT06126315 Not yet recruiting Phase 2/Phase 3 Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS June 2024 September 2026
NCT06147843 Not yet recruiting N/A French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis January 20, 2024 March 31, 2028
NCT06169696 Not yet recruiting N/A EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis November 2024 January 2025
NCT06181526 Not yet recruiting Phase 1 Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis December 15, 2023 October 30, 2024
NCT06230562 Not yet recruiting N/A DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease February 2024 August 2025
NCT06249867 Not yet recruiting Phase 2 A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS March 2024 June 2026
NCT06266403 Not yet recruiting N/A Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications April 2024 March 2029
NCT06280079 Not yet recruiting N/A Ultra-high-caloric, Fatty Diet in ALS May 1, 2024 May 1, 2027
NCT06315608 Not yet recruiting Phase 2 MRG-001 in Patients With Amyotrophic Lateral Sclerosis July 1, 2024 December 1, 2024
NCT06315673 Not yet recruiting Digital Assessment of Speech and Fine Motor Control in ALS June 1, 2024 March 30, 2027
NCT06365216 Not yet recruiting Phase 2 ALS Phase II Study of NX210c September 1, 2024 February 1, 2026
NCT06391645 Not yet recruiting Phase 2/Phase 3 Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis May 2024 December 2026
NCT06396260 Not yet recruiting N/A Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect May 23, 2024 December 31, 2026
NCT06441682 Not yet recruiting Phase 2 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) September 2, 2024 May 2027
NCT06450691 Not yet recruiting N/A Modeling Amyotrophic Lateral Sclerosis With Fibroblasts September 2024 September 2033
NCT05352958 Recruiting Contribution of Diaphragmatic Ultrasound for Monitoring Diaphragmatic Function in Patients With Amyotrophic Lateral Sclerosis May 16, 2023 November 2026
NCT05340660 Recruiting N/A mGluR5 Imaging in ALS Using PET April 2022 April 2025
NCT00136500 Recruiting Clinical Research in ALS Study February 2005 December 2027
NCT05407428 Recruiting A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS Patients May 31, 2022 November 30, 2024
NCT01772602 Recruiting The National Amyotrophic Lateral Sclerosis Registry October 2010 December 2030
NCT05358431 Recruiting N/A Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging Biomarkers July 21, 2022 February 21, 2026
NCT04998305 Recruiting Phase 1/Phase 2 TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps September 30, 2022 March 2024
NCT06219759 Recruiting Reinnervation and Neuromuscular Transmission in ALS May 2024 December 2026
NCT03567213 Recruiting N/A Investigation on the Cortical Communication (CortiCom) System December 14, 2021 August 31, 2026
NCT05336760 Recruiting Dysphagia, QoL and Attitudes Towards PEG in ALS Patients January 1, 2023 March 31, 2026
NCT05033951 Recruiting Optimizing INITIation of Non-invasive Ventilation in ALS Patients August 1, 2022 October 1, 2025
NCT05328492 Recruiting N/A Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis March 15, 2022 March 15, 2024
NCT05039099 Recruiting Phase 2 A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) September 2, 2021 January 18, 2025
NCT05309408 Recruiting A Longitudinal Analysis of Biomarkers in Patients With ALS June 11, 2021 September 2024
NCT05306457 Recruiting Phase 1 CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS May 8, 2022 September 2025
NCT04233099 Recruiting Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS) July 1, 2019 December 1, 2027
NCT05067179 Recruiting Analysis of Human ALS Tissues and Registry of ALS Patients September 1, 2020 August 30, 2025
NCT05095571 Recruiting N/A A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study October 7, 2021 December 31, 2026
NCT05104710 Recruiting Intermuscular Coherence as a Biomarker for ALS March 31, 2021 December 31, 2025
NCT06441448 Recruiting potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis January 1, 2024 December 31, 2024
NCT00912041 Recruiting N/A BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia May 2009 December 2038
NCT05107349 Recruiting N/A Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS) December 12, 2022 December 2025
NCT05116943 Recruiting Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders August 19, 2013 January 2030
NCT06344260 Recruiting Phase 2 Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS) January 25, 2024 September 2027
NCT05204017 Recruiting Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS September 12, 2021 July 2025
NCT05137665 Recruiting Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures January 1, 2021 December 31, 2031
NCT00317616 Recruiting The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study April 2006 December 2027
NCT05193994 Recruiting Phase 3 Triumeq in Amyotrophic Lateral Sclerosis February 24, 2022 July 1, 2026
NCT03944447 Recruiting Phase 2 Outcomes Mandate National Integration With Cannabis as Medicine December 1, 2018 December 31, 2025
NCT05189106 Recruiting Phase 1/Phase 2 Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial December 5, 2022 June 1, 2025
NCT03225144 Recruiting Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia October 11, 2017 October 30, 2025
NCT03217396 Recruiting Biomarkers of Synaptic Damage in Multiple Sclerosis November 22, 2017 September 30, 2027
NCT04008329 Recruiting A Registered Cohort Study on Amyotrophic Lateral Sclerosis July 5, 2019 July 2059
NCT06165172 Recruiting N/A Early Feasibility Study of the MyoRegulator® for Treatment of ALS June 21, 2023 July 31, 2024
NCT06337578 Recruiting Advances in Telephone-based Cognitive Screening Procedures October 25, 2023 October 25, 2026
NCT03127267 Recruiting Phase 3 Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients February 2, 2021 December 2023
NCT06325865 Recruiting Perception of Unpleasant Sensations During Study Procedures in ALS Patients April 19, 2023 December 2024
NCT03840928 Recruiting PatientSpot Formerly Known as ArthritisPower April 1, 2015 March 1, 2025
NCT03362658 Recruiting Novel MRI Biomarkers for Monitoring Disease Progression in ALS October 2016 December 31, 2024
NCT06318598 Recruiting Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis April 11, 2023 April 10, 2026
NCT06228001 Recruiting Holter of Movement in Patients With Amyotrophic Lateral Sclerosis. May 1, 2023 January 2028
NCT04363684 Recruiting ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) March 1, 2020 June 2025
NCT04380649 Recruiting N/A Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People February 13, 2023 February 2025
NCT06318585 Recruiting Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases April 3, 2023 December 31, 2026
NCT06094205 Recruiting N/A Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02) October 2024 August 31, 2027
NCT06083584 Recruiting Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis November 22, 2023 May 2025
NCT04057898 Recruiting Phase 2/Phase 3 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS May 28, 2020 December 2026
NCT04066244 Recruiting Phase 2 Study of Safety and of the Mechanism of BLZ945 in ALS Patients December 30, 2019 June 3, 2026
NCT06046599 Recruiting Remote Home Assessment of Patients With Amyotrophic Lateral Sclerosis October 24, 2022 February 1, 2024
NCT06021938 Recruiting N/A Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality April 4, 2024 April 4, 2026
NCT06008249 Recruiting Phase 3 Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS) August 9, 2021 June 2026
NCT04454892 Recruiting Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) November 1, 2019 December 1, 2030
NCT03835507 Recruiting Phase 1/Phase 2 Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis June 20, 2016 December 2025
NCT05983211 Recruiting N/A Quantitative and Repetitive TMS in ALS - Stage 2 May 1, 2024 April 15, 2027
NCT04468919 Recruiting N/A Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit July 15, 2022 June 30, 2025
NCT05979688 Recruiting N/A Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis November 1, 2023 August 28, 2025
NCT05974579 Recruiting Phase 1 Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis November 23, 2023 July 31, 2024
NCT05959850 Recruiting Phase 2 A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS June 13, 2023 December 2024
NCT05951556 Recruiting N/A Telehealth Implementation of Brain-Computer Interface September 30, 2021 July 5, 2024
NCT05928416 Recruiting ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach July 11, 2023 July 2025
NCT02869048 Recruiting Amyotrophic Lateral Sclerosis and the Innate Immune System June 2016 June 2026
NCT02795052 Recruiting N/A Neurologic Stem Cell Treatment Study June 2016 July 31, 2026
NCT04562831 Recruiting N/A The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. October 7, 2020 August 31, 2025
NCT04569435 Recruiting Phase 2 Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) January 15, 2021 January 2024
NCT04575727 Recruiting Early Phase 1 Exploratory Evaluation of [11C]MPC6827 January 8, 2021 September 2025
NCT06426030 Recruiting Validation of Czech Language Versions of Questionnaires for ALS Patients' Functional Status and Biomarker Long-term Follow-up May 17, 2024 September 30, 2024
NCT05882695 Recruiting Phase 1 Study of SPG302 in Healthy Volunteers and ALS Participants July 3, 2023 December 2025
NCT06418646 Recruiting Patients' and Caregivers' Views of Multidimensional Care in Amyotropic Lateral Sclerosis in Germany August 1, 2022 June 30, 2025
NCT02532244 Recruiting Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases June 2015 December 2025
NCT05852418 Recruiting Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases. October 30, 2015 June 2025
NCT05837507 Recruiting N/A Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange July 5, 2023 May 2025
NCT04691011 Recruiting N/A New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis June 16, 2021 December 31, 2026
NCT04695210 Recruiting N/A Virtual Peer-to-peer Support Programme for Carers of MND August 15, 2022 December 31, 2024
NCT05829330 Recruiting N/A Ambulatory Versus Inpatient Initiation of Home Mechanical Ventilation September 20, 2023 November 2024
NCT04721717 Recruiting AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis September 1, 2020 March 28, 2025
NCT04744532 Recruiting Phase 1/Phase 2 iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study March 19, 2019 March 31, 2024
NCT02360891 Recruiting Study of Predictive Factors of Progression of Motor Neurone Disease January 12, 2015 January 2026
NCT06215755 Recruiting Phase 1 A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS) January 15, 2024 June 2026
NCT05819931 Recruiting N/A Breathing With Amyotrophic Lateral Sclerosis August 29, 2023 December 31, 2026
NCT04768972 Recruiting Phase 3 FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) June 14, 2021 March 2028
NCT04097158 Recruiting Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone October 8, 2019 September 2024
NCT03489278 Recruiting Clinical Procedures to Support Research in ALS February 15, 2018 June 2025
NCT05768646 Recruiting Counterfactual Thinking in Amyotrophic Lateral Sclerosis March 31, 2021 September 30, 2023
NCT04798378 Recruiting N/A NuroSleeve Powered Brace & Stimulation System to Restore Arm Function April 16, 2020 December 2025
NCT05764434 Recruiting ALS Spinal Cord Gray and White Matter Study May 1, 2018 October 1, 2025
NCT04816227 Recruiting Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments September 29, 2021 October 30, 2027
NCT05753852 Recruiting Phase 3 Open Label Extension of TUDCA-ALS Study October 25, 2021 March 31, 2025
NCT04820478 Recruiting N/A Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS) April 1, 2022 October 1, 2025
NCT05747937 Recruiting N/A Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS May 15, 2021 December 30, 2024
NCT06206629 Recruiting Contralateral R1 in Amyotrophic Lateral Sclerosis February 15, 2024 February 15, 2025
NCT04858555 Recruiting Staging System in Amyotrophic Lateral Sclerosis December 2, 2022 December 2, 2024
NCT04875416 Recruiting Phenotype, Genotype and Biomarkers 2 January 8, 2021 August 2025
NCT06203106 Recruiting NYSCF Scientific Discovery Biobank November 10, 2022 November 10, 2045
NCT04882904 Recruiting N/A Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. September 25, 2020 January 2025
NCT04885374 Recruiting China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine March 1, 2021 March 1, 2028
NCT06201650 Recruiting Neurofilament Light Chain in Amyotrophic Lateral Sclerosis November 11, 2020 December 31, 2024
NCT04889898 Recruiting Remote Speech and Swallowing Assessment in ALS January 1, 2022 September 2024
NCT05744310 Recruiting N/A Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families April 21, 2023 August 21, 2032
NCT06429735 Recruiting N/A Precise Robotically IMplanted Brain-Computer InterfacE January 9, 2024 January 2031
NCT05724173 Recruiting N/A Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia October 18, 2023 December 2026
NCT05716074 Recruiting N/A The Effect of Low-İntensity Combined Exercises in Patients With Early Stage ALS. November 15, 2022 June 2023
NCT06172621 Recruiting N/A Spinal Cord Associative Plasticity for ALS April 1, 2024 February 29, 2028
NCT05695521 Recruiting Phase 1 Regulatory T Cells for Amyotrophic Lateral Sclerosis April 3, 2023 December 2027
NCT05633459 Recruiting Phase 1 A Study Evaluating the Safety and Tolerability of QRL-201 in ALS December 16, 2022 May 6, 2025
NCT05632757 Recruiting N/A Anticipated Patient and Caregiver Burden June 22, 2023 June 22, 2025
NCT05595850 Recruiting N/A A Mindful Community for People With ALS and Their Primary Caregivers October 12, 2023 July 31, 2024
NCT05562960 Recruiting N/A Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP May 1, 2023 March 31, 2025
NCT05542576 Recruiting Phase 1/Phase 2 AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy August 24, 2022 December 2023
NCT05498883 Recruiting N/A Quality of Life Evaluation With the SRI Questionnaire of ALS Patient With Non-invasive Ventilation September 13, 2022 September 13, 2024
NCT05474235 Recruiting Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders December 2007 December 2038
NCT06284161 Recruiting N/A QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up June 28, 2022 February 28, 2026
NCT05003921 Suspended Phase 1 Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS December 2022 September 2025
NCT01959373 Suspended N/A Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis October 2013
NCT01082653 Suspended Phase 1 Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis March 2010 May 2014
NCT03652805 Suspended Phase 1/Phase 2 A Study of IPL344 in the Treatment of ALS Patients August 1, 2018 February 2025
NCT00596115 Temporarily not available Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
NCT01992029 Terminated Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis June 17, 2014 October 22, 2015
NCT03948178 Terminated Phase 3 Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension June 26, 2019 November 18, 2020
NCT03377309 Terminated Phase 2 Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients December 1, 2019 July 1, 2021
NCT03334786 Terminated Phase 1/Phase 2 Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS April 5, 2018 August 23, 2018
NCT04226144 Terminated N/A Breath Stacking Technique Associated With Expiratory Muscle Training in Amyotrophic Lateral Sclerosis Patients January 6, 2020 December 1, 2022
NCT04248465 Terminated Phase 3 An Efficacy and Safety Study of Ravulizumab in ALS Participants March 30, 2020 October 17, 2021
NCT04288856 Terminated Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) April 28, 2020 May 3, 2022
NCT03090932 Terminated Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS January 18, 2016 November 13, 2020
NCT04326283 Terminated Phase 1/Phase 2 Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS) April 2, 2020 April 28, 2023
NCT04428775 Terminated Phase 2 A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease September 8, 2020 October 1, 2021
NCT03068754 Terminated Phase 2/Phase 3 Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) June 22, 2017 November 25, 2019
NCT03020797 Terminated N/A A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS) January 12, 2017 February 8, 2023
NCT04579666 Terminated Phase 2 MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) September 30, 2020 July 13, 2023
NCT04749433 Terminated Phase 1 Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS September 1, 2021 March 30, 2023
NCT02315339 Terminated European Home Mechanical Ventilation Registry August 2014 January 2019
NCT02269436 Terminated Phase 1 A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS January 2015 October 2015
NCT02058732 Terminated N/A Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis November 2013 September 30, 2015
NCT02000713 Terminated N/A Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS) October 2013 August 2015
NCT01999803 Terminated Phase 1 A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS September 2014 October 2015
NCT04944784 Terminated Phase 3 A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) August 16, 2021 July 18, 2023
NCT01950910 Terminated Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND) March 29, 2004 October 29, 2020
NCT01622088 Terminated Phase 3 Phase 3 Extension Study of Dexpramipexole in ALS June 2012 February 2013
NCT01583088 Terminated Phase 3 Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation September 2012 November 2015
NCT05053035 Terminated Phase 2 A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS September 2, 2021 October 28, 2022
NCT01384162 Terminated Phase 1/Phase 2 An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis June 2009 October 2015
NCT00159198 Terminated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia September 2002 June 2007
NCT01016522 Terminated Phase 3 Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) November 2009 January 2012
NCT00982150 Terminated Phase 2 Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) September 2009 June 2010
NCT05237284 Terminated Phase 2 Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) April 13, 2022 March 7, 2024
NCT00839033 Terminated Phase 3 Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders June 2009 December 2011
NCT00818389 Terminated Phase 2/Phase 3 Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) January 2009 October 2009
NCT00718445 Terminated Pennsylvania Consortium: Clinical Database March 2008 December 2015
NCT00718107 Terminated Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology June 2005 February 2012
NCT05442775 Terminated Phase 3 A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) July 25, 2022 June 7, 2023
NCT00718016 Terminated Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient December 2004 April 2009
NCT00718003 Terminated Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS). May 2005 February 2013
NCT00714220 Terminated Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS) November 2006 September 2014
NCT00690118 Terminated Phase 2 Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis May 2008 June 2010
NCT00160004 Terminated Phase 1/Phase 2 The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis March 2006 December 2008
NCT05866926 Terminated Phase 3 Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis March 6, 2023 February 22, 2024
NCT00537446 Terminated N/A Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis September 2007 August 2012
NCT00213824 Terminated A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis February 2004 July 2012
NCT03679975 Terminated Phase 2 Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS) April 4, 2018 December 21, 2018
NCT03757351 Terminated Phase 1 Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis December 14, 2018 June 18, 2020
NCT03613571 Terminated Phase 2 A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis August 15, 2018 August 20, 2019
NCT03836716 Terminated Phase 3 Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial September 19, 2019 July 2, 2021
NCT03519880 Terminated N/A A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects March 14, 2017 March 14, 2020
NCT04082832 Unknown status Phase 2/Phase 3 CuATSM Compared With Placebo for Treatment of ALS/MND September 30, 2019 December 30, 2020
NCT03900247 Unknown status N/A Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface March 18, 2019 December 31, 2022
NCT03764384 Unknown status Validation Of Tidal/End -Tidal CO2 in ALS August 20, 2018 June 4, 2021
NCT00673140 Unknown status Phase 1 Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) May 2008 June 2010
NCT01348451 Unknown status Phase 1 Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis January 2009 December 2016
NCT03579017 Unknown status Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Validation Study May 1, 2017 December 31, 2022
NCT01378026 Unknown status Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation January 2012
NCT01494480 Unknown status Phase 2 The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis March 2012 April 2015
NCT03578796 Unknown status Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study May 1, 2017 December 31, 2022
NCT05279755 Unknown status Phase 1 A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers February 26, 2022 July 2022
NCT00886977 Unknown status Phase 2 Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS) April 2009
NCT04953624 Unknown status Appetite and Related Factors in Patients With ALS August 1, 2020 March 31, 2022
NCT00004457 Unknown status Determinants of Disease Severity in Amyotrophic Lateral Sclerosis March 1998
NCT03806634 Unknown status Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2) March 1, 2019 September 1, 2020
NCT04918251 Unknown status EEG and TMS-based Biomarkers of ALS, MS and FTD September 2012 April 2023
NCT01530438 Unknown status N/A Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis April 2009 May 2015
NCT04953494 Unknown status Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis August 1, 2021 December 31, 2022
NCT01569958 Unknown status Phase 2 Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis July 2012 April 2016
NCT01650818 Unknown status N/A Aerobic Exercise Training in Amyotrophic Lateral Sclerosis January 2012 June 2014
NCT03806647 Unknown status Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 1) September 1, 2018 September 1, 2020
NCT01730716 Unknown status Phase 2 Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis May 2013 November 2016
NCT00753571 Unknown status Phase 2 Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response January 2008 October 2010
NCT02193893 Unknown status Phase 1 Biological Treatment of Amyotrophic Lateral Sclerosis January 2010 December 2017
NCT03573466 Unknown status N/A Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS April 10, 2019 May 25, 2023
NCT04953481 Unknown status Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis January 1, 2021 December 31, 2022
NCT04798183 Unknown status Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis March 1, 2021 April 30, 2021
NCT04762589 Unknown status Phase 2 RT001 in Amyotrophic Lateral Sclerosis March 10, 2021 September 30, 2022
NCT02374606 Unknown status Accurate Test of Limb Isometric Strength (ATLIS) in ALS March 2015 February 2020
NCT03367650 Unknown status N/A Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies May 13, 2014 May 13, 2023
NCT04686110 Unknown status N/A Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA February 12, 2021 February 2023
NCT00563537 Unknown status Phase 1 Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis January 2007 December 2010
NCT01897818 Unknown status N/A Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study July 2013
NCT03536962 Unknown status Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis June 1, 2012 October 1, 2018
NCT03452618 Unknown status N/A Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment December 14, 2017 December 14, 2022
NCT04651855 Unknown status Phase 1/Phase 2 The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS December 2, 2020 April 2023
NCT04952155 Unknown status Phase 2 Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome January 1, 2020 December 31, 2022
NCT04952038 Unknown status Sleep Disorders and the Onset and Progression of ALS August 1, 2020 March 31, 2022
NCT02665663 Unknown status N/A Tongue Strength in Amyotrophic Lateral Sclerosis (ALS) February 2016 July 2018
NCT04518540 Unknown status N/A Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis September 1, 2020 October 1, 2022
NCT00560287 Unknown status Phase 4 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis January 2008 August 2010
NCT04960540 Unknown status Multimodal Brain Imaging Study August 1, 2019 September 1, 2021
NCT02874209 Unknown status N/A Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis September 2015 September 2018
NCT02881476 Unknown status Phase 1 Therapeutic Treatment of Amyotrophic Lateral Sclerosis November 2015 December 2018
NCT02881489 Unknown status Phase 1 Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis November 2015 December 2018
NCT02917681 Unknown status Phase 1/Phase 2 Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis September 2016 August 2019
NCT03887338 Unknown status N/A Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway March 21, 2019 December 31, 2022
NCT03377868 Unknown status N/A Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis January 3, 2018 September 28, 2018
NCT01935518 Unknown status Phase 2 A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) September 2013 May 2015
NCT03049046 Unknown status Phase 1 CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS April 7, 2017 March 30, 2018
NCT03067857 Unknown status Phase 1/Phase 2 Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease September 2016 August 2019
NCT00331812 Unknown status Mitochondrial Functions and Oxidative Stress in ALS Patients February 2006 February 2008
NCT04950933 Unknown status Phase 2/Phase 3 The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules June 1, 2020 December 31, 2022
NCT04393467 Unknown status N/A Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS). May 31, 2020 December 2023
NCT04391361 Unknown status Phase 2 The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS November 1, 2020 October 31, 2023
NCT04328675 Unknown status Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China March 20, 2020 March 20, 2023
NCT03103815 Unknown status N/A Trial of Amivita in Amyotrophic Lateral Sclerosis April 24, 2017 October 20, 2018
NCT03136809 Unknown status Phase 1/Phase 2 ALS Treatment Extension Study January 18, 2018 December 31, 2022
NCT03214146 Unknown status Phase 1 Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS February 1, 2017 October 2021
NCT03272503 Unknown status Phase 2 A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) October 27, 2017 December 31, 2020
NCT04240925 Unknown status N/A Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease May 25, 2018 December 31, 2022
NCT03285204 Unknown status Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia July 2015 February 2020
NCT03296501 Unknown status Phase 1 Intraspinal Transplantation of Autologous ADRC in ALS Patients October 13, 2015 October 31, 2022
NCT04150809 Unknown status A Study to Explore the Role of Gut Flora in ALS March 2, 2020 July 2023
NCT04140136 Unknown status Phase 2 The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) June 17, 2019 September 1, 2020
NCT03321487 Unknown status N/A Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis April 13, 2018 December 30, 2022
NCT04950647 Unknown status Phase 2 Efficacy and Safety of Nitrazine in the Treatment of ALS July 1, 2020 December 31, 2022
NCT04956822 Unknown status Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases June 1, 2018 December 1, 2022
NCT03981536 Unknown status Phase 1 A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) October 10, 2019 November 2, 2020
NCT03694132 Unknown status N/A Brain Excitability and Connectivity in Sensory-motor Pathways in ALS November 26, 2018 April 6, 2022
NCT03548311 Unknown status Phase 3 Clinical Trial of Ultra-high Dose Methylcobalamin for ALS November 1, 2017 March 31, 2020
NCT03034317 Withdrawn N/A NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS) February 2, 2017 February 12, 2018
NCT03843710 Withdrawn Phase 2 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) March 2020 March 2022
NCT01954875 Withdrawn Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases December 2, 2009 July 2, 2019
NCT01984814 Withdrawn Phase 2 Stem Cell Therapy for Amyotrophic Lateral Sclerosis December 2008 August 2013
NCT03474263 Withdrawn Phase 2 IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) September 1, 2019 July 12, 2021
NCT02116634 Withdrawn Phase 1/Phase 2 Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis May 2015 May 2017
NCT02242071 Withdrawn Phase 1 Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis December 2008 September 2016
NCT05830214 Withdrawn Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS January 2024 February 6, 2024
NCT02405403 Withdrawn Early Phase 1 Microglial Activation Role In ALS (MARIA) March 2015 March 2017
NCT02588807 Withdrawn Phase 1 Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis January 1, 2021 May 2022
NCT00561366 Withdrawn Phase 2 A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
NCT05949294 Withdrawn Phase 1 Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) January 2024 March 2025
NCT04468191 Withdrawn N/A Fatigue in Patients With Amyotrophic Lateral Sclerosis February 10, 2021 February 10, 2021
NCT03338114 Withdrawn Phase 1/Phase 2 Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS November 2017 August 2018
NCT03076632 Withdrawn N/A Interactions Between Neurostimulation and Physical Exercise April 1, 2017 September 26, 2017
NCT03892382 Withdrawn N/A Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis November 15, 2019 December 31, 2021
NCT03892863 Withdrawn N/A Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis November 15, 2019 December 31, 2021
NCT03664206 Withdrawn Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy February 16, 2018 February 1, 2024
NCT03659422 Withdrawn N/A Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis July 1, 2019 July 1, 2021
NCT03508453 Withdrawn Phase 2 IC14 for Treatment of Amyotrophic Lateral Sclerosis August 15, 2019 December 15, 2021
NCT00846560 Withdrawn Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS) August 2008 July 2009
NCT05041114 Withdrawn N/A SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis April 21, 2022 November 30, 2022
NCT01565395 Withdrawn Phase 2 Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) March 2012 July 2013
NCT01759784 Withdrawn Phase 1 Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS March 2014
Disase is a (Disease Ontology)
DOID:231
Cross Reference ID (Disease Ontology)
GARD:5786
Cross Reference ID (Disease Ontology)
ICD10CM:G12.21
Cross Reference ID (Disease Ontology)
ICD9CM:335.20
Cross Reference ID (Disease Ontology)
KEGG:05014
Cross Reference ID (Disease Ontology)
MESH:D000690
Cross Reference ID (Disease Ontology)
MIM:PS105400
Cross Reference ID (Disease Ontology)
NCI:C34373
Cross Reference ID (Disease Ontology)
ORDO:803
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:86044005
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0002736
Exact Synonym (Disease Ontology)
ALS
Exact Synonym (Disease Ontology)
Lou Gehrig's disease
Exact Synonym (Disease Ontology)
motor neuron disease, bulbar
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0007354
OMIM Phenotype Series Number (OMIM)
PS105400
OrphaNumber from OrphaNet (Orphanet)
803
MeSH unique ID (MeSH (Medical Subject Headings))
D000690